10 Oct 2022 Bionest Are the Blues Ending for Bluebird? Gene therapy developer bluebird bio may be turning a corner, with recent FDA approvals for two of its rare disease therapeutics.
28 Mar 2022 Bionest ASH 2021 Update: Part 2 A look at new hematology therapy developments for hemophilia, beta thalassemia and sickle cell disease presented at ASH 2021.